Register Login

LIQUIDIA CORP (LQDA)

(85% Positive) LIQUIDIA CORP (LQDA) Announces Enrollment Update for approved Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Sept. 3, 2026, 12:01 p.m.

    📋 LIQUIDIA CORP (LQDA) - Clinical Trial Update

    Filing Date: 2026-09-03

    Accepted: 2026-09-03 08:00:31

    Event Type: Clinical Trial Update

    Event Details:

    LIQUIDIA CORP (LQDA) Announces Clinical Trial Update LIQUIDIA CORP (LQDA) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: approved, YUTREPIA
    • Diseases/Conditions: SSc-RP is currently under clinical development, SSc-RP
    • Collaboration: the Treatment of Raynaud's

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: LIQUIDIA CORP
    • Ticker Symbol: LQDA

Search

News categories